Introducing JAMA’s Research of the Year. Chosen by JAMA editors, the inaugural roundup highlights 9 of the most impactful, newsworthy, and novel studies published in the journal over the past year. 🧵 #JAMAROTY25 🔗 https://t.co/zvpFrvH0Os

Introducing JAMA’s Research of the Year. #JAMAROTY25 Chosen by JAMA editors, the inaugural roundup highlights 9 of the most impactful, newsworthy, and novel studies published in the journal over the past year: Learn more: https://t.co/iteyyXfw3S

🆕 https://t.co/TZ3m3IFod1 Onchain has integrated @dYdX 🙌 📈 You can now trade in the Onchain app with up to 50x leverage 🪙 Access over 200+ trading pairs ⚡ Start trading instantly with no bridging, switching, with no extra steps Trade Now👇 https://t.co/LA0ZA2FdBm

The WISDOM randomized clinical trial presented at #SABCS25 finds that risk-based #BreastCancer screening safely matches annual screening for stage ≥IIB cancers in women aged 40 to 74 years. 🎥 Watch the video and read the full study: https://t.co/eRWVP6PmFt

In WISDOM, researchers compared risk-based breast cancer screening to standard annual mammography among more than 28 000 US women aged 40 to 74 across all 50 states. #SABCS25 @SABCSSanAntonio https://t.co/HIhZoxqsut

@SABCSSanAntonio 💬 Editorial: In a JAMA Original Investigation presented at #SABCS25, trialists found risk-based screening was as safe as annual screening for detecting advanced cancers but did not reduce breast biopsy rates. https://t.co/HMccinpdEj

What if your money could do more than grow? Robin John’s new book shows you how your investments can honor God and serve your neighbor. Join the Good Investor Movement and start investing with purpose!

In a JAMA #RCT presented at #SABCS25, researchers found risk-based breast cancer screening was as safe as annual screening for detecting advanced cancers but did not reduce breast biopsy rates. 🧵 @SABCSSanAntonio https://t.co/9jnJt8Xj5W

To learn more about JAMA’s Research of the Year 2025, read the full article from JAMA Medical News: ➡️ https://t.co/zvpFrvH0Os

🚨Honored to share our new study in @JAMA_current: Nearly 1 in 3 U.S. adults has metabolic syndrome, and the burden has not improved over the past decade: ⚠️Key Findings: 🚩Metabolic syndrome remains strikingly common–affecting about 39% of U.S. adults with no meaningful

#JAMAROTY25: Semaglutide and Tirzepatide in Patients with HFpEF #Semaglutide and #Tirzepatide were both associated with a more than 40% lower risk of heart failure hospitalization or all-cause death in patients with cardiometabolic #HFpEF compared with a placebo proxy. 🔗

Bring the LTX-2 API into real production pipelines, powering 4K, 50fps, synchronized-audio video generation

#JAMAROTY25: US POINTER Randomized Clinical Trial Among older adults with #dementia risk factors, structured lifestyle support led to greater improvements in global cognition than self-guided changes. 🔗 https://t.co/yuJ5cTdjia

#JAMAROTY25: Launch-HTN Randomized Clinical Trial In adults with uncontrolled #hypertension taking multiple antihypertensive medications, the aldosterone synthase inhibitor lorundrostat safely lowered systolic blood pressure compared with placebo. 🔗 https://t.co/DMaAcRa38D

#JAMAROTY25: Herpes Zoster Vaccination and Dementia Occurrence Eligibility for #herpes zoster vaccination based on date of birth in the Australian National Immunisation Programme was associated with a reduction in the probability of receiving a new diagnosis of #dementia over

#JAMAROTY25: GUARDIAN study Targeted genome sequencing for #NewbornScreening enabled early detection of treatable conditions missed by standard tests, with broad parental consent and successful delivery across diverse groups. 🔗 https://t.co/Fbx2FuyUXv

Built by the team who brought you Baldur's Gate 3, Larian Studios unchains its ambitions to bring you an RPG with greater breadth & depth than ever before. Divinity - The gods are silent. Rivellon bleeds. New powers stir.

#JAMAROTY25: Testing and Evaluation of Health Care Applications of Large Language Models #AI in health care is rapidly expanding, but there are major gaps in how these #LLM applications are assessed. Evaluations rarely use real patient data, and many overlook performance on

#JAMAROTY25: The TRAIN Randomized Clinical Trial In patients with acute brain injury and anemia, a more liberal red blood cell transfusion strategy improved neurological outcomes compared with a restrictive strategy. 🔗 https://t.co/y8DZAct0iQ

#JAMAROTY25: The BEe-HIVe Randomized Clinical Trial In people with #HIV who didn’t respond to prior #HepB vaccination, a vaccine with a novel adjuvant provided better seroprotection than the conventional vaccine. 🔗 https://t.co/Z4h21ukcqX

#JAMAROTY25: The COMET Randomized Clinical Trial Active monitoring for low-risk #DCIS was noninferior to standard treatment over 2 years, with similar rates of invasive cancer and fewer mastectomies compared with guideline-concordant care. 🔗 https://t.co/E1l7gTf4SB

If you want to spot the highest performing stocks in the market, this exclusive charting tool is your secret weapon.

Approximately 39% of US adults met criteria for metabolic syndrome in 2023, with persistent disparities by age and race highlighting the need for ongoing preventive efforts. https://t.co/yAsNiril4z

This JAMA Patient Page describes hypothyroidism and its risk factors, signs and symptoms, diagnosis, screening, and treatment. https://t.co/PySRGtp80V

Postpartum hemorrhage is an obstetric emergency that has an incidence of 3% to 6% of births and accounts for approximately 27% of maternal deaths worldwide. Learn more about the risk factors, assessment, and management of PPH: https://t.co/RPXx6TeCbw